ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Dental evaluation protocols from MASCC/ISOO/ASCO for patients beginning an osteoclast inhibitor based on type of dental and/or periodontal pathology

Dental evaluation protocols from MASCC/ISOO/ASCO for patients beginning an osteoclast inhibitor based on type of dental and/or periodontal pathology
Dental pathology Complete Partial Minimal, incomplete, or no clearance
Caries Restore all teeth Restore mild/moderate caries if time permitted Intervention only if symptomatic
Severe caries/pulp involvement/dental abscess Root canal treatment or extract    
Apical periodontitis Retreat Treat symptomatic lesions and all lesions ≥5 mm  
Apicoectomy Observe asymptomatic lesions and all lesions <5 mm  
Extract    
Advanced periodontal disease Extract teeth with: Extract teeth with:  
Probing depth ≥6 mm Probing depth ≥8 mm  
Furcation I, II, III Mobility III  
Severe inflammation Severe inflammation  
Partially erupted third molars Extract Observe asymptomatic teeth  
  Extract partially erupted third molars with purulence associated with pericoronitis  
NOTE: The proper protocol should be selected by the oncologist and dentist according to the patient's medical status. Complete care is optimal dental evaluation prior to initiating osteoclast inhibitor therapy; partial care may be needed in patients for whom complete care is not possible either because of cost or medical condition; minimal care may be necessary for patients in need of prompt or emergency initiation of osteoclast inhibitor therapy secondary to rapidly progressive bone metastases or hypercalcemia requiring therapy.
MASCC: Multinational Association of Supportive Care in Cancer; ISOO: International Society of Oral Oncology; ASCO: American Society of Clinical Oncology.
Adapted with permission from: Springer: Supportive Care in Cancer. Hong CHL, Hu S, Haverman T, et al. A systematic review of dental disease management in cancer patients. Support Care Cancer 2018; 26:155. Copyright © 2018. https://link.springer.com/journal/520.
Adaptations reaffirmed by:
  1. Yarom N, Shapiro CL, Peterson DE, et al. Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline. J Clin Oncol 2019.
Graphic 121989 Version 6.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟